Life Science REITs Explained

REIT · Baker 1031 Research · Updated June 2026 · 16 min read

I keep seeing people describe lab real estate as if its specialized construction alone settles the investment case. It does not. The buildings can be hard to replicate, the tenants can be reluctant to move, and the rents can be higher than office rents. Yet the value of those advantages still depends on funding, new supply, tenant credit, and the health of a small number of markets.

That is the useful distinction between first-order and second-order thinking here. First-order thinking sees scarce lab space, premium rents, and powerful medical research. Second-order thinking asks whether a wave of supply is arriving just as biotech financing weakens, whether tenants can fund their work, and whether a portfolio is too dependent on one cluster. Price and risk meet at that intersection.

Life science REITs own laboratory and research buildings leased to biotechnology, pharmaceutical, and research tenants. The guide below covers what those REITs own, the demand behind them, specialized-space economics, funding-cycle risk, the supply pipeline, and how to evaluate the sector. Demand, returns, and outlook are discussed in general, non-promissory terms. Past performance doesn't guarantee future results. Verify current conditions; this is educational information, not investment advice.

For a wider comparison among property types, see our comprehensive REIT primer.

What Life Science REITs Own

Life science REITs own purpose-built laboratory and research real estate, not ordinary office buildings. Their properties serve biotechnology companies, pharmaceutical firms, and research organizations using wet labs, dry labs, and specialized research space. A lab building is engineered for scientific work: advanced HVAC and ventilation manage fume hoods and frequent air exchanges; redundant power supports sensitive work; specialized plumbing carries lab gases and water; vibration control protects instruments; and floors and ceilings are often built to more demanding specifications than those of a typical office.

That infrastructure makes laboratory space more expensive to build and difficult to retrofit from conventional space. It can support higher rents and a meaningful replacement-cost barrier. It also explains why the building is not simply interchangeable with office space.

Geography matters just as much. Life science real estate is concentrated in innovation hubs where research universities, scientific talent, venture capital, established companies, collaborators, and suppliers gather. The Boston and Cambridge area, the San Francisco Bay Area, and San Diego are leading examples, alongside a handful of emerging clusters. A life science REIT therefore often has material exposure to the health of specific clusters—their talent pools, capital availability, and construction pipeline.

Biotech & Pharma Demand

Demand for life science real estate follows biotechnology and pharmaceutical research and development. Companies expanding their pipelines, scaling research, or forming new ventures need room for scientists, instruments, and experiments. An aging population, advances in genomics and drug discovery, and continuing investment in life sciences are longer-run sources of support. That is part of why the sector is often grouped with growth REITs investing for appreciation.

Still, no broad trend turns a lease into a certainty. A portfolio can range from large, creditworthy pharmaceutical companies and established biotechs to smaller early-stage startups developing their first products. The former may offer stronger credit and stability. The latter may offer growth, but many are pre-revenue and dependent on outside capital. Demand is structurally supported, but it is also cyclical and sensitive to the condition of the biotech and pharma funding market.

Lab space sells an ecosystem as much as square footage. Tenants pay to be near talent, universities, collaborators, and capital. That is why activity concentrates in relatively few markets.

Specialized Lab Space

The economic appeal of life science REITs begins with specialization. Purpose-built labs need sophisticated HVAC and ventilation, redundant high-capacity power, specialized gas and water systems, vibration isolation, and structural features conventional offices do not need. The equipment and infrastructure are costly to build and difficult to add later. Limited high-quality supply and high replacement cost can support premium rents in well-located buildings.

Specialization can also make tenants sticky. Once a biotech or pharma company has installed equipment, validated clean rooms, and configured space for ongoing research, moving can be financially costly and disruptive to experiments. That gives a tenant an incentive to stay and renew, which can support occupancy and rent stability.

But the same feature creates a constraint. If a lab tenant leaves, the owner may have a narrower pool of replacement users than an office landlord would. Not every business needs—or wants to pay for—laboratory infrastructure. Specialized space can therefore be both a source of premium rent and a re-leasing risk.

Funding-Cycle Risk

Funding-cycle risk is the sector's defining vulnerability. Lab demand is tied closely to biotech venture capital and research funding. When venture capital is abundant and biotech IPO and financing markets are open, startups can raise money, expand, and lease additional lab space. When funding tightens—through a biotech downturn, a venture-capital pullback, or a difficult financing environment—early-stage and pre-revenue tenants may slow expansion, give back space, or fail. Demand can decline and vacancy can rise.

This makes life science REITs more cyclical than their high-rent, specialized space might suggest. The risk is especially acute when new lab buildings are delivered into a softening funding environment: rising vacancy and weaker demand can pressure rents and occupancy at the same time. Smaller, earlier-stage tenants tend to be more exposed; larger, well-capitalized pharma and established biotech tenants are generally more resilient. The tenant mix and the amount of speculative new supply determine how sensitive a portfolio is to the cycle.

Key Takeaways

• Life science REITs own purpose-built lab and research space, engineered for science and concentrated in hubs such as Boston/Cambridge, the Bay Area, and San Diego.
• Biotech and pharma R&D growth drives demand, but tenants span large, creditworthy firms and riskier early-stage startups.
• Specialized lab space is costly to build, hard to replicate, capable of premium rents, and can keep tenants in place; it can also be harder to re-lease to non-lab users.
• Funding-cycle risk is the central weakness: a downturn in biotech venture and research funding can reduce demand and raise vacancy.

Supply Pipeline and Market Concentration

The supply pipeline deserves as much attention as demand. When developers respond to a strong period by building aggressively in popular clusters, a substantial amount of new laboratory space can arrive over several years. If demand remains strong, that space may be absorbed. If it arrives during a funding downturn, abundant new inventory and rising vacancy can pressure market rents and occupancy.

Market concentration compounds the issue. A REIT concentrated in one cluster is more exposed to that market's funding conditions, talent pool, and construction pipeline than a REIT diversified across several hubs. Strong submarkets and properties anchored by larger, creditworthy tenants may provide some cushion, but they do not remove cluster-specific risk.

Two observable variables often matter most: how much new construction is coming online in each cluster, and how readily biotech funding can support tenants that need to occupy it.

Evaluating Life Science REITs

Start with location and cluster quality. Which innovation hubs are represented? How deep and durable are their ecosystems of talent, universities, and capital? How diversified is the portfolio across markets? A REIT in strong, established clusters with diversified exposure is generally better positioned than one concentrated in a single less-proven market.

Then look at tenant credit and stage. What percentage of rent comes from large, creditworthy pharmaceutical companies and established, well-funded biotechs, and what percentage comes from small, early-stage, funding-dependent startups? A tenant base weighted toward stronger credit is generally more resilient during a funding downturn.

Next, examine the supply pipeline in every important market. Compare new space being delivered with demand. Consider the REIT's leverage and balance sheet, building quality and modernity, lease terms and retention, and tenant-mix exposure to funding-cycle risk. Demand and outlook should be treated as general and non-promissory: biotech funding is cyclical, distributions aren't guaranteed, and share prices fluctuate. Past performance doesn't guarantee future results. Current cluster conditions, funding climate, and supply pipelines should be verified independently rather than inferred from a recent strong period.

How Baker 1031 Helps You Evaluate Life Science REITs

Baker 1031 Investments helps investors understand the specialized lab and research space these REITs own, the biotech and pharma demand behind it, the premium-rent and tenant-retention logic, funding-cycle risk, the supply pipeline, and whether the sector fits their goals. Where appropriate, it helps investors access suitable offerings.

REIT and non-traded-REIT interests and related securities are offered through the broker-dealer, Aurora Securities, Inc. (member FINRA/SIPC), and any recommendation follows a suitability review. Non-traded and private REITs typically require accredited or otherwise suitable investors. Publicly traded REITs trade through ordinary brokerage accounts. Baker 1031 does not provide tax or legal advice; your CPA and attorney handle your specific tax situation, including how REIT dividends are taxed. Yields and returns are never promised. Distributions can be cut, share prices fluctuate, and current funding and supply conditions should be verified. The purpose is to evaluate the sector clearly and invest only when it is suitable for your goals and risk tolerance.

Frequently Asked Questions

What is a life science REIT?

A life science REIT is a Real Estate Investment Trust that owns specialized laboratory and research real estate and leases it to biotechnology, pharmaceutical, and research tenants. The buildings include advanced HVAC and ventilation, high-capacity and redundant power, specialized gas and water systems, vibration control, and structural features that ordinary offices lack. That makes them costly to construct and hard to replicate. The properties cluster in hubs such as Boston/Cambridge, the San Francisco Bay Area, and San Diego, where research universities, talent, venture capital, and companies congregate. The REIT collects rent and distributes most of its income to shareholders under the usual REIT rules.

What do life science REITs own?

They own purpose-built wet labs, dry labs, and research buildings designed for science rather than conventional office use. The buildings support fume hoods and air exchange through advanced ventilation and HVAC, provide redundant high-capacity power, lab-gas and water plumbing, vibration isolation, and higher floor loads and ceiling heights. They are generally concentrated in Boston/Cambridge, the Bay Area, San Diego, and other emerging hubs because tenants need access to talent, universities, collaborators, and capital.

What drives demand for life science real estate?

Biotech and pharmaceutical R&D growth drives demand. When companies expand pipelines, launch ventures, or scale research, they need room for scientists, instruments, and experiments. Aging demographics, genomics, drug discovery, and life-science investment are longer-run supports. But demand depends on funding. Large, creditworthy pharma and established biotech firms differ from early-stage startups that may be pre-revenue and dependent on outside capital. Well-funded periods can produce robust demand; funding contractions can soften it.

Why does specialized lab space command higher rents?

It costs more to build and is harder to reproduce than office space. Advanced air handling, high-capacity power, gas and water systems, vibration isolation, and more demanding structural features increase replacement cost and limit high-quality supply. Once a tenant has built out and validated a lab, moving can disrupt research and be expensive, creating an incentive to renew. The trade-off is that a vacant lab can be harder to re-lease to a non-lab business.

What is funding-cycle risk for life science REITs?

Funding-cycle risk means lab demand rises and falls with biotech venture capital and research funding. Early-stage tenants, especially pre-revenue companies, often depend on outside capital rather than operating profit. Open financing markets can support expansion and leasing. A biotech downturn or venture pullback can lead tenants to slow expansion, return space, or fail, lifting vacancy. The effect is concentrated among funding-dependent tenants and can worsen when new speculative lab supply arrives at the same time.

Where is life science real estate concentrated?

Leading clusters include the Boston and Cambridge area, the San Francisco Bay Area, and San Diego, along with a handful of emerging markets. Companies locate near universities, scientific talent, venture capital, collaborators, and suppliers. Because a portfolio is often concentrated in these specific markets, its building values can be tied to local funding climate, talent, and supply pipeline. One-cluster concentration generally brings more exposure to that market's swings than several-hub diversification.

Are life science REITs a good investment?

Whether one fits depends on your goals and risk tolerance. The appeal is specialized, hard-to-replicate lab space, potentially premium rents, sticky tenants, and long-run support from aging demographics and scientific research. The risks are equally specific: demand is tied to biotech funding, new supply can pressure rents, portfolios can be concentrated in a few hubs, and many tenants may be early-stage and funding-dependent. Distributions aren't guaranteed and share prices fluctuate. Size the exposure appropriately, and verify current funding and supply conditions rather than assuming them.

How is lab space different from office space?

Laboratory space is engineered for science. It requires advanced HVAC and ventilation for fume hoods and frequent air exchanges, redundant high-capacity power, specialized plumbing, vibration isolation, stronger floors, and higher ceilings. It is more expensive to build and harder to retrofit, which can limit supply and support higher rents. It also can keep a tenant in place after a costly buildout. Office space is generally cheaper, more interchangeable, and easier to re-lease to a broad tenant base. Lab space may be more difficult to repurpose for non-lab users.

What happens to life science REITs in a biotech downturn?

Pressure can be real. Tight funding, cooler IPO and financing markets, and a venture pullback can cause early-stage tenants to slow expansion, give back space, or fail, reducing demand and increasing vacancy. New supply delivered at that moment can further pressure rents and occupancy. Larger, well-capitalized pharma and established biotech tenants are generally more resilient and continue paying rent. A portfolio anchored by creditworthy tenants in strong clusters is usually better placed than one leaning heavily on early-stage tenants and speculative supply.

How does the supply pipeline affect life science REITs?

The pipeline is the amount of new lab construction under way or being delivered in each market. In a healthy demand period, new space can be absorbed. In a funding downturn, new inventory and rising vacancy can pressure rents and occupancy, sometimes sharply. An oversupplied cluster can affect every REIT exposed to it. A REIT that built or bought near the arrival of a large supply wave may face headwinds; markets with limited new supply can be more disciplined.

How do I evaluate the tenants of a life science REIT?

Assess tenant credit and development stage. Large, creditworthy pharmaceutical companies and well-funded established biotechs generally offer more stability than small, early-stage startups that are pre-revenue and rely on outside funding. Review the share of rent from each group, lease terms, retention, and whether the tenant base is diversified across companies, stages, and clusters. Then consider how that mix interacts with each cluster's supply pipeline and funding environment.

Are life science REITs cyclical?

Yes. Their specialized, high-rent space may appear defensive, but many tenants depend on biotech venture capital and research funding. When funding is abundant, demand can be strong. When it tightens, startups may contract or fail and vacancy can rise. New lab supply in a weakening market adds to the strain. The sector also has long-run support from an aging population and advances in biotech and pharma research, and larger, well-capitalized tenants can be more resilient. Tenant mix and supply exposure determine how cyclical a particular portfolio actually is.

How do interest rates affect life science REITs?

Like most REITs, life science REITs are sensitive to rates. Higher bond yields can make a REIT distribution comparatively less attractive and weigh on share prices even if rent is unchanged. Higher borrowing costs can make acquisitions and development less economic. Tighter financial conditions may also coincide with a more difficult biotech funding environment, so tenant demand and the REIT's cost of capital can be stressed together. Specialized space and long leases offer some insulation, but investors should examine leverage, debt maturities, and the interaction between rates and biotech funding. Past performance doesn't guarantee future results; verify current conditions.

Why is lab space hard to replace if a tenant leaves?

The features that retain a tenant can narrow the replacement pool. Advanced ventilation, redundant power, specialized gas and water systems, and vibration control have little use for a conventional business, and potential replacement users are mostly other lab tenants in the same clusters. In a well-funded market, a well-located building may find another lab user. During a funding downturn, fewer companies may be expanding, re-leasing can take longer, and concessions may be needed. A deep, well-funded hub generally has a broader potential tenant base than a thin or fading market.

How does Baker 1031 help me evaluate life science REITs?

Baker 1031 helps investors understand what these REITs own, the demand behind specialized space, premium-rent and sticky-tenant economics, funding-cycle risk, and the supply pipeline. It helps weigh cluster quality, tenant credit and stage, leverage, and funding exposure. REIT and non-traded-REIT interests are offered through Aurora Securities, Inc. (member FINRA/SIPC), and recommendations follow a suitability review. Non-traded and private REITs typically require accredited or otherwise suitable investors, while publicly traded REITs are available through ordinary brokerage. Baker 1031 does not provide tax or legal advice; your CPA handles your individual situation, including REIT-dividend taxation. Returns are not promised, past performance doesn't guarantee future results, and current conditions should be verified.

Glossary

Life Science REIT: A REIT that owns lab and research space leased to biotech and pharma tenants.

Lab Space: Purpose-built laboratory real estate engineered for scientific work.

Wet Lab: Lab space equipped for experiments using liquids, chemicals, or biologics.

Innovation Cluster: A hub where life-science talent, capital, and companies concentrate.

Biotech: Companies developing therapies using biological science and technology.

Pharma Tenant: A pharmaceutical company leasing research or lab space.

Venture Capital: Funding that backs early-stage biotech and shapes lab demand.

Funding-Cycle Risk: Demand tied to biotech funding, which rises and falls in cycles.

Tenant Credit Quality: The financial strength of a tenant backing the rent.

Tenant Stage: Where a tenant sits from early-stage startup to established firm.

Specialized Infrastructure: Advanced HVAC, power, and systems that lab space requires.

Replacement Cost: The cost to rebuild specialized lab space, which supports rents.

Sticky Tenant: A tenant unlikely to move because relocation is costly and disruptive.

Supply Pipeline: New lab construction being delivered into a market.

90% Distribution Rule: The REIT requirement to pay out at least 90% of taxable income.

Suitability Review: Assessing whether an offering fits the investor before recommending it.

Sources & References

1. U.S. Securities and Exchange Commission: Investor.gov — Real Estate Investment Trusts (REITs)
2. Nareit: What's a REIT (Real Estate Investment Trust)?
3. FINRA: Real Estate Investments
4. IRS: About Form 1099-DIV, Dividends and Distributions

Disclosures

This article is published by Baker 1031 Investments, LLC for general educational purposes for accredited investors and is not an offer to sell or a solicitation of an offer to buy any security, nor is it tax, legal, accounting, or investment advice or a recommendation. Any securities offering is made solely through a sponsor’s private placement memorandum (PPM) following a suitability determination. Securities offered through Aurora Securities, Inc. (ASI), member FINRA / SIPC; Baker 1031 Investments is independent of ASI.

Oil & gas mineral and royalty interests and DST programs are speculative, illiquid securities sold only to verified accredited investors and involve substantial risk, including possible loss of principal, commodity-price and production-decline risk, lack of control, and the risk that an intended 1031 exchange fails to qualify for tax deferral. Whether a particular interest qualifies as like-kind real property is a fact-specific legal determination that varies by state and by the terms of the instrument. Tax results depend on your individual circumstances. Consult your own CPA and attorney before acting. Past performance does not guarantee future results.

Filed under: REIT · REITs

About the author

Jerry Baker is Founder & Managing Principal of Baker 1031 Investments (FINRA Series 22 / 63 · SIE). Jerry founded Baker 1031 to bring institutional underwriting discipline to the 1031 exchange. He spent more than a decade on Wall Street working on $10B+ of real estate before building diversified DST portfolios for individual investors. Read full bio.

The profile describes him as a former Wall Street real estate professional involved in more than $10 billion of transactions who brings institutional underwriting discipline to 1031 exchanges and Delaware Statutory Trusts. He attended Babson College. The listed areas of expertise are Delaware Statutory Trusts, 1031 Exchange, 721 UPREIT Exchange, Opportunity Zone Funds, Mineral & Royalty Interests, and REITs.

The listed award is GlobeSt. CRE's Aspiring Leaders of 2026, reflected in GlobeSt.com's CRE's Aspiring Leaders of 2026 article. His credentials are FINRA Series 22 — Direct Participation Programs Limited Representative, FINRA Series 63 — Uniform Securities Agent State Law, and FINRA SIE — Securities Industry Essentials; each is recognized by FINRA. Personal profile destinations are BrokerCheck and LinkedIn.

Reviewed by: Lori Kamen — President & CCO, Aurora Securities, Inc. (FINRA Series 4 / 7 / 24 / 53 / 63 / 66), the supervising registered principal. Last reviewed June 2026. Baker 1031 reviews its educational content periodically for accuracy and regulatory compliance. Securities offered through Aurora Securities, member FINRA/SIPC.

Explore current offerings

See the REITs currently available and how they may fit a strategy like this one: View REITs. Educational only — not an offer of any security. Offerings are available to verified, accredited investors and change over time.

I am managing risk in this part of real estate by demanding a margin for weaker funding, a realistic view of new supply, and tenant credit that can withstand a tougher cycle. How are you weighing specialized-space scarcity against funding and supply risk today?